Value of fusing PET plus CT images in hepatocellular carcinoma and combined hepatocellular and cholangiocarcinoma patients with extrahepatic metastases: Preliminary findings

Liver International

Volumn 26, Issue 7, 2006, Pages 781-788

  Nagaoka, Sakae ^a   Itano, Satoshi ^a   Ishibashi, Masatoshi ^a   Torimura, Takuji ^a   Baba, Kenkichi ^a   Akiyoshi, Junji ^a   Kurogi, Junichi ^a   Matsugaki, Satoru ^a   Inoue, Kinya ^a   Tajiri, Nobuyoshi ^a   Takada, Akio ^a   Ando, Eiji ^a   Kuromatsu, Ryoko ^a   Kaida, Hayato ^a   Kurogi, Mina ^a   Koga, Hironori ^a   Kumashiro, Ryukichi ^a   Hayabuchi, Naofumi ^a   Kojiro, Masamichi ^a   Sata, Michio ^a  

^a KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

18F FDG PET; Hepatocellular carcinoma; PET CT

Indexed keywords

FLUORODEOXYGLUCOSE F 18; MEDRONATE TECHNETIUM TC 99M;

ADULT; ADVANCED CANCER; AGED; ARTICLE; BILE DUCT CARCINOMA; BONE METASTASIS; BONE SCINTISCANNING; CLINICAL ARTICLE; CLINICAL TRIAL; COMPUTER ASSISTED TOMOGRAPHY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DIAPHRAGM DISEASE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; KIDNEY METASTASIS; LIVER CELL CARCINOMA; LUNG METASTASIS; LYMPH NODE METASTASIS; MALE; METASTASIS; PERITONEUM METASTASIS; POSITRON EMISSION TOMOGRAPHY; SENSITIVITY ANALYSIS; SKIN METASTASIS; SPLEEN TUMOR; STOMACH CANCER;

ADULT; AGED; AGED, 80 AND OVER; BILE DUCT NEOPLASMS; BILE DUCTS, INTRAHEPATIC; CARCINOMA, HEPATOCELLULAR; CHOLANGIOCARCINOMA; FEMALE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS, MULTIPLE PRIMARY; POSITRON-EMISSION TOMOGRAPHY; PREDICTIVE VALUE OF TESTS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 33746723467     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/j.1478-3231.2006.01296.x     Document Type: Article

References (23)

1. El Serag H B, Mason A C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999; 340: 745-50.
2. Parkin D M, Bray F, Ferlay J, Pisani P. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001; 94: 153-6.
3. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 1996; 334: 693-9.
4. Arii S, Yamaoka Y, Futagawa S, et al. Results of surgical and nonsurgical treatment for small-sized hepatocellular carcinomas: A retrospective and nationwide survey in Japan. The Liver Cancer Study Group of Japan. Hepatology 2000; 32: 1224-9.
5. Llovet J M, Real M I, Montana X, et al. Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: A randomised controlled trial. Lancet 2002; 359: 1734-9.
6. Rigo P, Paulus P, Kaschten B J, et al. Oncological apllication of positron emission tomography with fluorine-18 fluorodeoxyglucose. Eur J Nucl Med 1996; 23: 1641-74.
7. Giannopoulou C. The role of SPECT and PET in monitoring tumor response to therapy. Eur J Nucl Med Mol Imaging 2003; 30: 1173-200.
8. Khan M A, Combs C S, Brunt E M, et al. Positron emission tomography scanning in the evaluation of hepatocellular carcinoma. J Hepatol 2000; 32: 792-7.
9. Trojan J, Schroeder O, Raedle J, et al. Fluorine-18 FDG positron emission tomography for imaging of hepatocellular carcinoma. Am J Gastroenterol 1999; 94: 3314-9.
10. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med 1995; 36: 1811-7.
11. Edmondson H A Steiner P. Primary carcinoma of the liver: A study of 100 cases among 48,900 necropsies. Cancer 1954; 7: 462-503.
12. Gibson J. Histogogical Typing of Tumors of the Liver, Biliary Tract, and Pancreas. Geneva, Switzerland: World Health Organization, 1978.
13. 18 F-FDG PET in the detection of extrahepatic metastasis from hepatocellular carcinoma. J Gastroenterol 2004; 39: 961-8.
14. Kaczynski J, Hansson G, Wallerstedt S. Metastases in cases with hepatocellular carcinoma in relation to clinicopathologic features of the tumor. An autopsy study from a low endemic area. Acta Oncol 1995; 34: 43-8.
15. Maillefert J F, Tebib J, Quipourt V, et al. Normal technetium 99m diphosphonate bone scintigraphy in skeletal metastases from hepatocellular carcinoma. J Hepatol 1994; 21: 684.
16. Katyal S, Oliver J H III, Peterson M S, Ferris J V, Carr B S, Baron R L. Extrahepatic metastases of hepatocellular carcinoma. Radiology 2000; 216: 698-703.
17. Bradley J D, Dehdashti F, Muntun M A, Ramaswamy G, Trinkaus K Siegel B A. Positron emission tomography in limited-stage small-cell lung cancer: a prospective study. J Clin Oncol 2004; 22: 3248-54.
18. Cook G J, Houston S, Rubens R, Maisey M N, Fogelman I. Detection of bone metastases in breast cancer with FDG-PET. Differing matabolic activity in osteoblastic and ostelytic lesion. J Clin Oncol 1998; 16: 3375-9.
19. Ghanem N, Uhl M, Brink I, et al. Diagnostic value of MRI in comparison to scintigraphy, PET, MS-CT and PET/CT for the detection of metastases of bone. Eur Radiol 2005; 55: 41-55.
20. Schoder H, Erdi Y E, Larson S M, Yeung H W D. PET/CT: A new imaging technology in nuclear medicine. Eur J Nucl Med Mol Imaging 2003; 30: 1419-37.
21. Schlitt H J, Neipp M, Weimann A, et al. Recurrence patterns of hepatocellular carcinoma and fibrolamellar carcionma after liver transplantation. J Clin Oncol 1999; 17: 324-31.
22. Torizuka T, Tamaki N, Inokuma T, et al. Value of Fluorine-18 FDG PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med 1994; 35: 1965-9.
23. Jerusalem G, Beguin Y, Fassotte M F, et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment in Hodgikin's disease and non-Hodgikin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. Blood 1999; 94: 429-33.